SCHEMBL17874170

SCHEMBL17874170

COc1ccc(C=CC(N)=O)c(N)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.43
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
JUN P05412 1/20 0.42
NFKB1 P19838 1/20 0.42
CYP1A1 P04798 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP1B1 Q16678 1/20 0.42
NFE2L2 Q16236 2/20 0.41
TFEB P19484 1/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
ABCB1 P08183 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
APP P05067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4601971 0.87 ABCG2 (0.49) ABCG2MAPTALDH1A1MEN1KMT2A
SCHEMBL4601970 0.87 ABCG2 (0.49) ABCG2MAPTALDH1A1MEN1KMT2A
SCHEMBL28267297 0.78 ABCG2 (0.69) ABCG2MAPTALDH1A1KMT2ACYP1A1
SCHEMBL26402804 0.78 ABCG2 (0.69) ABCG2MAPTALDH1A1KMT2ACYP1A1
SCHEMBL17913647 0.76 ALDH1A1 (0.47) MAPTALDH1A1KMT2AKDM4ELMNA
SCHEMBL27642544 0.76 ABCG2 (0.44) ABCG2MAPTALDH1A1MEN1KMT2A
SCHEMBL1477685 0.73 NFE2L2 (0.74) MAPTALDH1A1MEN1KMT2ACYP1A1
SCHEMBL1379749 0.73 NFE2L2 (0.74) MAPTALDH1A1MEN1KMT2ACYP1A1
SCHEMBL1477777 0.73 NFE2L2 (0.74) MAPTALDH1A1MEN1KMT2ACYP1A1
SCHEMBL29913403 0.73 NFE2L2 (0.74) MAPTALDH1A1MEN1KMT2ACYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016105525-A2 NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-06-30 WO claimed
WO-2020200158-A1 N-HETEROAROMATIC AMIDE DERIVATIVES FOR TREATMENT OF CANCER 深圳福沃药业有限公司 2020-10-08 WO disclosed
WO-2020192302-A1 PYRIMIDINE-CONTAINING TRI-SUBSTITUTED IMIDAZOLE COMPOUND AND APPLICATION THEREOF 广州必贝特医药技术有限公司 2020-10-01 WO disclosed